BPC-157 + TB-500: the “Wolverine stack” research guide

BPC-157 + TB-500 — the “Wolverine stack”. The BPC-157 + TB-500 pairing is the canonical combination cited across tendon, ligament and soft-tissue research literature — two peptides co-lyophilised in a single vial, often referenced as the “Wolverine stack”. This guide is a research-reference summary for Australian researchers: what each component does, why they are combined, and how the blend is verified. It makes no performance, medical, or human-use claim.

Two peptides, two pathways, one research model

The blend is a formulation rather than a single chemical entity, so it carries no single CAS number or molecular weight — each component has its own identity. BPC-157 (a synthetic 15-residue pentadecapeptide) is referenced around growth-factor / nitric-oxide signalling and VEGFR2-associated angiogenesis; TB-500 (thymosin β-4, the 43-residue actin-sequestering peptide) is referenced around actin-polymerisation dynamics. The pairing is the canonical “soft-tissue stack” because the two act on distinct pathways that converge on the same tissue-repair research model.

The research behind each component

BPC-157’s reported nitric-oxide-system interaction and VEGFR2-associated angiogenic signalling are covered by Seiwerth and colleagues (Frontiers in Pharmacology, 2021), with the pro-angiogenic VEGFR2 mechanism reported by Hsieh and colleagues (Journal of Molecular Medicine, 2017). TB-500 / thymosin β-4’s role as a regulator of actin polymerisation in living cells was shown by Sanders and colleagues (Proceedings of the National Academy of Sciences, 1992), and its broader regenerative biochemistry is reviewed by Goldstein and colleagues (Expert Opinion on Biological Therapy, 2012). Researchers reference the literature for each peptide separately; the BPC-157 and TB-500 guides cover each in depth.

Why the blend — and how it is tested

The co-lyophilised vial reconstitutes both peptides together rather than across two — a research-methodology convenience for protocols that reference both compounds. Each component is still independently HPLC-content-tested by Janoshik; because it is a multi-peptide vial, the certificate reports per-peptide content (BPC-157 and TB-500 separately) rather than a single combined purity figure — research-honest, not marketing-shorthand. The certificate is published on the product page and in the lab-reports library; nothing is listed without certificates on file.

Reconstitution and handling for research use

Reconstitute the co-lyophilised vial with bacteriostatic water for laboratory handling; the per-peptide content on the certificate of analysis is the reference for the concentration math. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window.

Compliance and research-use framing

Neither component is TGA-approved and neither is a therapeutic good. Elite AU Peptides supplies the blend strictly for in-vitro and laboratory research use only — not for human or animal consumption, with no medical, performance, or human-use claim about the blend or its components. Researchers should consult primary peer-reviewed sources for each component’s pathway data.